Respiratory Syncytial Virus Vaccine Enters Clinical Testing
February 22, 2017
February 22, 2017
WASHINGTON, Feb. 22 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release:
A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial also will assess the vaccine's ability to prompt an immune response in healthy adult participa . . .
A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial also will assess the vaccine's ability to prompt an immune response in healthy adult participa . . .